Table 2

Surgical and post-operative data for overall population (n=365) and according to chemotherapy response score (CRS)

Overall
(n=365)
CRS 1–2 (n=277)CRS 3 (n=88)P value
PCI, n (%)
 ≤10
 >10
 Median (range)
 Missing
205 (56.5)
158 (43.5)
9 (0–39)
2 (-)
132 (47.8)
144 (52.2)
11 (0–39)
1 (-)
73 (83.9)
14 (16.1)
4 (0–19)
1 (-)
<0.001
NACT, n (%)
 3–4 cycles
 6 cycles
219 (60.0)
146 (40.0)
174 (62.8)
103 (37.2)
45 (51.1)
43 (48.9)
0.051
CC-score
 CC-0
 CC-1
318 (87.1)
47 (12.9)
231 (83.4)
46 (16.6)
87 (98.9)
1 (1.1)
<0.001
Aletti score, n (%)
 <8
 ≥8
213 (58.4)
152 (41.6)
139 (50.2)
138 (49.8)
74 (84.1)
14 (15.9)
<0.001
Post-operative complications*, grade III/IV, n (%)
 No
 Yes
294 (80.5)
71 (19.5)
218 (78.7)
59 (21.3)
76 (86.4)
12 (13.6)
0.114
Bevacizumab maintenance, n (%)
 No
 Yes
290 (79.5)
75 (20.5)
213 (76.9)
64 (23.1)
77 (87.5)
11 (12.5)
0.032
Platinum resistance†, n (%)
 *No
 Yes
 Missing
272 (77.5)
79 (22.5)
14 (-)
194 (73.5)
70 (26.5)
13 (-)
78 (89.7)
9 (10.3)
1 (-)
0.002
  • *Platinum resistance defined as early relapse within 6 months after last cycle of carboplatin.

  • †Clavien-Dindo classification.

  • CC, complete cytoreduction; CRS, chemotherapy response score; NACT, neoadjuvant chemotherapy; PCI, peritoneal cancer index.